Equities research analysts expect Haemonetics Corporation (NYSE:HAE) to report earnings per share (EPS) of $0.44 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Haemonetics’ earnings. The highest EPS estimate is $0.46 and the lowest is $0.41. Haemonetics reported earnings of $0.43 per share during the same quarter last year, which would indicate a positive year over year growth rate of 2.3%. The company is scheduled to report its next earnings results before the market opens on Tuesday, February 6th.

According to Zacks, analysts expect that Haemonetics will report full-year earnings of $1.69 per share for the current fiscal year, with EPS estimates ranging from $1.66 to $1.72. For the next year, analysts anticipate that the firm will post earnings of $1.90 per share, with EPS estimates ranging from $1.75 to $2.07. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Haemonetics.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The business had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. During the same quarter last year, the business posted $0.38 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis.

A number of equities analysts recently weighed in on the company. Zacks Investment Research lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Jefferies Group increased their price target on Haemonetics from $18.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, January 8th. Raymond James Financial upgraded Haemonetics from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 2nd. Morgan Stanley upgraded Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price target for the company in a research report on Tuesday, January 2nd. Finally, Barrington Research increased their price target on Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $58.83.

Haemonetics (NYSE HAE) opened at $64.12 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51. Haemonetics has a 1 year low of $36.44 and a 1 year high of $64.99. The firm has a market capitalization of $3,386.71, a price-to-earnings ratio of 801.60, a P/E/G ratio of 4.84 and a beta of 0.99.

In related news, Director Mark W. Kroll sold 7,118 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $63.00, for a total value of $448,434.00. Following the completion of the sale, the director now directly owns 33,881 shares of the company’s stock, valued at approximately $2,134,503. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Susan Bartlett Foote sold 16,926 shares of the stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $54.19, for a total value of $917,219.94. Following the completion of the sale, the director now directly owns 27,313 shares of the company’s stock, valued at $1,480,091.47. The disclosure for this sale can be found here. Insiders sold a total of 54,486 shares of company stock valued at $3,050,827 in the last quarter. 1.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Haemonetics by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 4,743,044 shares of the medical instruments supplier’s stock worth $187,303,000 after acquiring an additional 48,719 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Haemonetics by 18.7% in the 3rd quarter. Victory Capital Management Inc. now owns 2,414,526 shares of the medical instruments supplier’s stock worth $108,340,000 after acquiring an additional 381,012 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in Haemonetics by 10.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 2,053,458 shares of the medical instruments supplier’s stock worth $92,139,000 after acquiring an additional 189,797 shares in the last quarter. HealthCor Management L.P. lifted its stake in Haemonetics by 15.9% in the 2nd quarter. HealthCor Management L.P. now owns 1,854,872 shares of the medical instruments supplier’s stock worth $73,249,000 after acquiring an additional 254,872 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Haemonetics by 2.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,739,734 shares of the medical instruments supplier’s stock worth $68,702,000 after acquiring an additional 40,381 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “$0.44 EPS Expected for Haemonetics Corporation (HAE) This Quarter” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/15/0-44-eps-expected-for-haemonetics-corporation-hae-this-quarter-2.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.